Patents Assigned to ESBATech
-
Patent number: 10221237Abstract: The invention provides methods of using sequence based analysis and rational strategies to improve the solubility of immunobinders, and in particular of single chain antibodies (scFvs). The invention provides methods of engineering immunobinders, and in particular scFvs, by performing one or more substitutions with hydrophilic residues identified by analysis of a database of selected, stable scFv sequences. The invention also provides immunobinders with optimized solubility prepared according to the engineering methods of the invention.Type: GrantFiled: December 14, 2016Date of Patent: March 5, 2019Assignee: ESBATech, an Alcon Biomedical Research Unit LLCInventors: Leonardo Borras, David Urech
-
Patent number: 10125186Abstract: Compositions are provided, which can be used as frameworks for the creation of very stable and soluble single-chain Fv antibody fragments. These frameworks have been selected for intracellular performance and are thus ideally suited for the creation of scFv antibody fragments or scFv antibody libraries for applications where stability and solubility are limiting factors for the performance of antibody fragments, such as in the reducing environment of a cell. Such frameworks can also be used to identify highly conserved residues and consensus sequences which demonstrate enhanced solubility and stability.Type: GrantFiled: November 1, 2016Date of Patent: November 13, 2018Assignee: ESBATech, an Alcon Biomedical Research Unit LLCInventors: Kathrin Tissot, Stefan Ewert, Adrian Auf Der Maur, Alcide Barberis, Dominik Escher
-
Patent number: 10100111Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF-mediated disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: GrantFiled: May 18, 2016Date of Patent: October 16, 2018Assignee: ESBATech, an Alcon Biomedical Research Unit LLCInventors: Leonardo Borras, Tea Gunde, David Urech
-
Patent number: 10093726Abstract: The present invention provides sustained-release pharmaceutical formulations for administering proteins to the eye. In particular, the invention provides formulations comprising single chain antibodies and hydrophobic polyester hexylsubstituted poly(lactic acid) (hexPLA). The invention further provides processes for the production of sustained-release pharmaceutical formulations and medical uses thereof.Type: GrantFiled: August 24, 2016Date of Patent: October 9, 2018Assignee: ESBATech, an Alcon Biomedical Research Unit LLCInventors: Lutz Asmus, Michael Möller, Robert Gurny, John P. A. Grimshaw
-
Patent number: 10087244Abstract: The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.Type: GrantFiled: December 10, 2015Date of Patent: October 2, 2018Assignee: ESBATech, an Alcon Biomedical Research Unit LLCInventors: Leonardo Jose Borras, David Urech
-
Publication number: 20180127493Abstract: The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.Type: ApplicationFiled: December 18, 2017Publication date: May 10, 2018Applicant: ESBATech, an Alcon Biomedical Research Unit LLCInventors: Leonardo Borras, David Urech
-
Patent number: 9938336Abstract: The invention provides methods of using sequence based analysis and rational strategies to modify and improve the structural and biophysical properties of single chain antibodies (scFvs), including stability, solubility, and antigen binding affinity. These methods and strategies can be used individually or in combination. The methods of the present invention also include the use of a database comprising scFv sequences from an experimentally screened scFv library of antibodies that have been selected to have superior solubility and stability. The invention also provides methods of using the properties found for these selected antibodies in a general approach for reshaping scFv antibodies to improve stability and solubility properties of a single chain antibody fragment.Type: GrantFiled: August 23, 2012Date of Patent: April 10, 2018Assignee: Esbatech, an Alcon Biomedical Research Unit LLCInventors: David M. Urech, Leonardo Borras
-
Patent number: 9908945Abstract: The invention provides methods of using sequence based analysis and rational strategies to modify and improve the structural and biophysical properties of single chain antibodies (scFvs), including stability, solubility, and antigen binding affinity. These methods and strategies can be used individually or in combination. The methods of the present invention also include the use of a database comprising scFv sequences from an experimentally screened scFv library of antibodies that have been selected to have superior solubility and stability. The invention also provides methods of using the properties found for these selected antibodies in a general approach for reshaping scFv antibodies to improve stability and solubility properties of a single chain antibody fragment.Type: GrantFiled: June 25, 2008Date of Patent: March 6, 2018Assignee: Esbatech, An Alcon Biomedical Research Unit LLCInventors: David Urech, Leonardo Borras
-
Patent number: 9908940Abstract: The invention provides methods for identifying immunobinders, such as scFv antibodies, capable of specifically binding to cell surface antigens, and compositions identified according to said methods.Type: GrantFiled: November 20, 2015Date of Patent: March 6, 2018Assignee: Esbatech, An Alcon Biomedical Research Unit LLCInventors: David Urech, Valerie Hulmann-Cottier
-
Patent number: 9873737Abstract: The present invention relates to soluble and stable anti-VEGF imunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: GrantFiled: June 16, 2015Date of Patent: January 23, 2018Assignee: ESBATech, an Alcon Biomedical Research Unit LLCInventors: Leonardo Borras, David Urech, Tea Gunde
-
Patent number: 9873736Abstract: The present invention provides sustained-release pharmaceutical formulations for administering proteins to the eye. In particular, the invention provides formulations comprising single chain antibodies and hydrophobic polyester hexylsubstituted poly(lactic acid) (hexPLA). The invention further provides processes for the production of sustained-release pharmaceutical formulations and medical uses thereof.Type: GrantFiled: August 18, 2014Date of Patent: January 23, 2018Assignee: ESBATech, an Alcon Biomedical Research Unit LLCInventors: Lutz Asmus, Michael Möller, Robert Gurny, John P. A. Grimshaw
-
Patent number: 9803027Abstract: A method for decreasing the immunogenicity of antibody variable domains is disclosed.Type: GrantFiled: June 19, 2014Date of Patent: October 31, 2017Assignee: ESBATech, an Alcon Biomedical Research Unit LLCInventors: David Urech, Leonardo Jose Borras
-
Patent number: 9683034Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF?, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF?, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF?-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: GrantFiled: March 8, 2016Date of Patent: June 20, 2017Assignee: ESBATech, an Alcon Biomedical Research Unit LLCInventors: Stefan Ewert, David Urech, Adrian Auf Der Maur, Alcide Barberis, Peter Lichtlen
-
Publication number: 20170096482Abstract: The invention provides methods of using sequence based analysis and rational strategies to improve the solubility of immunobinders, and in particular of single chain antibodies (scFvs). The invention provides methods of engineering immunobinders, and in particular scFvs, by performing one or more substitutions with hydrophilic residues identified by analysis of a database of selected, stable scFv sequences. The invention also provides immunobinders with optimized solubility prepared according to the engineering methods of the invention.Type: ApplicationFiled: December 14, 2016Publication date: April 6, 2017Applicant: ESBATech, an Alcon Biomedical Research Unit LLCInventors: Leonardo Borras, David Urech
-
Patent number: 9598487Abstract: The invention provides antibodies that are modified to reduce aggregration propensity, and methods of producing such antibodies. The present invention also provides particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: GrantFiled: August 28, 2013Date of Patent: March 21, 2017Assignee: ESBATech, an Alcon Biomedical Unit LLCInventors: Leonardo Jose Borras, David Urech
-
Patent number: 9593161Abstract: The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.Type: GrantFiled: February 12, 2014Date of Patent: March 14, 2017Assignee: ESBATech, an Alcon Biomedical Research Unit LLCInventors: Leonardo Jose Borras, David Urech
-
Patent number: 9556265Abstract: The invention provides methods of using sequence based analysis and rational strategies to improve the solubility of immunobinders, and in particular of single chain antibodies (scFvs). The invention provides methods of engineering immunobinders, and in particular scFvs, by performing one or more substitutions with hydrophilic residues identified by analysis of a database of selected, stable scFv sequences. The invention also provides immunobinders with optimized solubility prepared according to the engineering methods of the invention.Type: GrantFiled: June 25, 2009Date of Patent: January 31, 2017Assignee: ESBATech, an Alcon Biomedical Research Unit LLCInventors: Leonardo Borras, David Urech
-
Patent number: 9518108Abstract: Compositions are provided, which can be used as frameworks for the creation of very stable and soluble single-chain Fv antibody fragments. These frameworks have been selected for intracellular performance and are thus ideally suited for the creation of scFv antibody fragments or scFv antibody libraries for applications where stability and solubility are limiting factors for the performance of antibody fragments, such as in the reducing environment of a cell. Such frameworks can also be used to identify highly conserved residues and consensus sequences which demonstrate enhanced solubility and stability.Type: GrantFiled: August 26, 2014Date of Patent: December 13, 2016Assignee: ESBATech, an Alcon Biomedical Research Unit LLCInventors: Kathrin Tissot, Stefan Ewert, Adrian Auf Der Maur, Alcide Barberis, Dominik Escher
-
Patent number: 9422366Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF-mediated disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: GrantFiled: December 19, 2013Date of Patent: August 23, 2016Assignee: Esbatech, An Alcon Biomedical Research Unit LLCInventors: Leonardo Borras, Tea Gunde, David Urech
-
Patent number: 9403903Abstract: The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.Type: GrantFiled: May 7, 2015Date of Patent: August 2, 2016Assignee: ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLCInventor: Dominik Escher